Cardiff Oncology Inc expected to post a loss of 17 cents a share - Earnings Preview

Cardiff Oncology

01/11/2021 11:07

* Cardiff Oncology Inc  CRDF.OQ   CRDF.O  is expected to show a
fall in quarterly revenue when it reports results on November 3
(estimated). 
* The San Diego, California-based company is expected to report 
a 77.9% decrease in revenue to $30 thousand from $136 thousand a
year ago, according to the mean estimate from 4 analysts, based
on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Cardiff Oncology Inc is
for a loss of 17 cents per share. For the same quarter last
year, the company reported a loss of 19 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Cardiff
Oncology Inc is $25​, about 76.5% above​ its last closing price
of $5.87. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 30 2021  -0.15       -0.15      -0.17     Missed  -13.5
 Mar. 31 2021  -0.16       -0.15      -0.14     Beat    5.1
 Dec. 31 2020  -0.15       -0.14      -0.19     Missed  -35.7​
 Sep. 30 2020  -0.19       -0.19      -0.19     Met     -1.8
 Jun.          -0.24​      -0.24      -0.51     Missed  -112.5
 30​ 2020​                                              ​
                                                        ​
 Dec. 31 2019  -0.79       -0.57      -0.51     Beat    11.3
 Sep. 30 2019  -0.84       -0.84      -0.71     Beat    15.5
 This summary was machine generated November 1 at 11:07 GMT.  All
figures in US dollars unless otherwise stated